Literature DB >> 9815858

Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations.

K E McKenzie1, A Siva, S Maier, I B Runnebaum, R Seshadri, S Sukumar.   

Abstract

Seventy-five to 80% of breast cancers are negative for p53 gene mutations. We have investigated the possibility that altered WAF1 genes provide an alternative mode of cell cycle disruption in these tumors. DNA from a total of 85 primary breast tumors and cell lines from both the United States and Australia were examined for WAF1 and p53 mutations. With the exception of one primary tumor containing the polymorphic codon 31 (AGC-->AGA), no missense mutations in the WAF1 gene were found in 33 primary tumors or in the 19 cell lines from the United States. By contrast, 2 of 33 tumors from Australia contained tumor-specific missense mutations in the WAF1 gene, while an additional six cases contained the AGC-->AGA polymorphic 31st codon in the WAF1 gene. The p53 mutation frequency in the Australian cohort (18%) was found to be similar to that reported by us (Glebov et al., Cancer Res., 54: 3703-3709, 1994; Runnebaum et al., Proc. Natl. Acad. Sci. USA, 88: 10657-10661, 1991) in the tumors of United States patients (13%) with sporadic breast cancer. Thus, mutations in the WAF1 gene are rare in tumors with or without p53 mutations, suggesting that except in a minor population of breast cancer patients of Caucasian origin, cell cycle dysregulation by mutated p53 or WAF1 genes may not contribute to breast tumor initiation or progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815858

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

1.  Aberrant promoter hypermethylation of p21 (WAF1/CIP1) gene and its impact on expression and role of polymorphism in the risk of breast cancer.

Authors:  Marjan Askari; Ranbir Chander Sobti; Mohsen Nikbakht; Suresh C Sharma
Journal:  Mol Cell Biochem       Date:  2013-09-05       Impact factor: 3.396

2.  Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors.

Authors:  Li-Ju Chang; Alan Eastman
Journal:  Cell Cycle       Date:  2012-05-01       Impact factor: 4.534

Review 3.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

Review 4.  Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.

Authors:  Shogo Ohkoshi; Masahiko Yano; Yasunobu Matsuda
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

5.  Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas.

Authors:  Jessica Costa-Guda; Chen-Pang Soong; Vaishali I Parekh; Sunita K Agarwal; Andrew Arnold
Journal:  Horm Cancer       Date:  2013-05-29       Impact factor: 3.869

6.  Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.

Authors:  L J Valente; S Grabow; C J Vandenberg; A Strasser; A Janic
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

7.  Formulation of Small Activating RNA Into Lipidoid Nanoparticles Inhibits Xenograft Prostate Tumor Growth by Inducing p21 Expression.

Authors:  Robert F Place; Ji Wang; Emily J Noonan; Rachel Meyers; Muthiah Manoharan; Klaus Charisse; Rick Duncan; Vera Huang; Xiaoling Wang; Long-Cheng Li
Journal:  Mol Ther Nucleic Acids       Date:  2012-03-27       Impact factor: 10.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.